Published in Healthcare Finance, Tax and Law Weekly, January 10th, 2007
Among the 27 patients evaluable for response, study results showed the FPD-R regimen with pixantrone produced an 89% overall response rate (ORR), including 63% of patients experiencing a complete disappearance of their disease (complete response, CR). The results were presented at the 48th Annual Meeting of the American Society of Hematology (ASH). The estimated median duration of response was 25 months and the estimated progression-free survival rate at 3 years...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Finance, Tax and Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.